Related Experiment Video
Updated: Dec 27, 2025
Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
Published on: June 9, 2023
Hydroxygenkwanin Suppresses Non-Small Cell Lung Cancer Progression by Enhancing EGFR Degradation
Yann-Lii Leu1,2, Tong-Hong Wang3,4, Chih-Ching Wu5,6
1Graduate Institute of Natural Products, Chang Gung University, Taoyuan 333, Taiwan.
Abstract:
Epidermal growth factor receptor (EGFR) is frequently overexpressed and mutated in non-small cell lung cancer (NSCLC), which is the major type of lung cancer. The EGFR tyrosine kinase inhibitors (TKIs) are the approved treatment for patients harboring activating mutations in the EGFR kinase. However, most of the patients treated with EGFR-TKIs developed resistance. Therefore, the development of compounds exhibiting unique antitumor activities might help to improve the management of NSCLC patients. The total flavonoids from Daphne genkwa Sieb. et Zucc. have been shown to contain antitumor activity. Here, we have isolated a novel flavonoid hydroxygenkwanin (HGK) that displays selective cytotoxic effects on all of the NSCLC cells tested. In this study, we employed NSCLC cells harboring EGFR mutations and xenograft mouse model to examine the antitumor activity of HGK on TKI-resistant NSCLC cells. The results showed that HGK suppressed cancer cell viability both in vitro and in vivo. Whole-transcriptome analysis suggests that EGFR is a potential upstream regulator that is involved in the gene expression changes affected by HGK. In support of this analysis, we presented evidence that HGK reduced the level of EGFR and inhibited several EGFR-downstream signalings. These results suggest that the antitumor activity of HGK against TKI-resistant NSCLC cells acts by enhancing the degradation of EGFR.
Insights
A novel flavonoid, hydroxygenkwanin (HGK), shows promise against TKI-resistant non-small cell lung cancer (NSCLC). HGK suppresses tumor growth by enhancing epidermal growth factor receptor (EGFR) degradation, offering a new therapeutic avenue for NSCLC patients.
Area of Science:
- Oncology
- Pharmacology
- Molecular Biology
Background:
- Non-small cell lung cancer (NSCLC) frequently exhibits epidermal growth factor receptor (EGFR) mutations, making EGFR tyrosine kinase inhibitors (TKIs) a primary treatment.
- Acquired resistance to EGFR-TKIs is a significant clinical challenge in NSCLC management.
- Natural compounds, like flavonoids from *Daphne genkwa*, are explored for novel antitumor activities.
Purpose of the Study:
- To investigate the antitumor activity of a novel flavonoid, hydroxygenkwanin (HGK), against TKI-resistant NSCLC cells.
- To elucidate the mechanism of action of HGK, focusing on its effects on EGFR signaling pathways.
- To evaluate the efficacy of HGK in preclinical models of TKI-resistant NSCLC.
Main Methods:
- Isolation and characterization of hydroxygenkwanin (HGK) from *Daphne genkwa* flavonoids.
- In vitro assessment of HGK's cytotoxic effects on NSCLC cell lines with EGFR mutations.
- In vivo evaluation of HGK's antitumor activity using a xenograft mouse model.
- Whole-transcriptome analysis to identify molecular targets and pathways affected by HGK.
- Western blot analysis to examine EGFR levels and downstream signaling inhibition.
Main Results:
- HGK demonstrated selective cytotoxic effects on tested NSCLC cells, including TKI-resistant lines.
- HGK suppressed cancer cell viability both in vitro and in vivo.
- Whole-transcriptome analysis implicated EGFR as a potential upstream regulator affected by HGK.
- HGK treatment led to reduced EGFR levels and inhibition of EGFR-downstream signaling pathways.
- Evidence suggests HGK enhances EGFR degradation, contributing to its antitumor activity.
Conclusions:
- Hydroxygenkwanin (HGK) exhibits significant antitumor activity against TKI-resistant NSCLC.
- The mechanism involves the enhancement of EGFR degradation and subsequent inhibition of downstream signaling.
- HGK represents a potential therapeutic candidate for overcoming TKI resistance in NSCLC.
Related Concept Videos
01:24Regulation of Angiogenesis and Blood Supply
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:53Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:12Loss of Tumor Suppressor Gene Functions
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
03:03mTOR Signaling and Cancer Progression
The mTOR pathway or the...